← Eichor
Condition: Stargardt Macular Dystrophy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Stargardt Macular Dystrophy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Phase N/A · 8 location(s) · Ascidian Therapeutics, Inc · NCT06445322Inherited Retinal Degenerative Disease Registry
Phase N/A · 1 location(s) · Foundation Fighting Blindness · NCT02435940An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
EARLY_Phase 1 · 1 location(s) · HuidaGene Therapeutics Co., Ltd. · NCT07063251Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
NA · 1 location(s) · Science Corporation · NCT07266584A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficac
Phase 1/Phase 2 · 5 location(s) · Splice Bio · NCT06942572Phase 1 Study of C.001 in Retinal Degeneration
Phase 1 · 1 location(s) · Cellio Therapeutics Inc · NCT07594236Study of ALK-001 on the Progression of Stargardt Disease
Phase 3 · 5 location(s) · Alkeus Pharmaceuticals, Inc. · NCT07419334The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Phase 1 · 1 location(s) · University of Rochester · NCT06319872Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Phase 1/Phase 2 · 10 location(s) · Ascidian Therapeutics, Inc · NCT06467344An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Au
Phase N/A · 20 location(s) · Splice Bio · NCT06435000A Study of DC6001 Tablet in Healthy Chinese Adult Subjects
Phase 1 · 1 location(s) · Heronova Pharmaceuticals · NCT07417566A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Phase N/A · 12 location(s) · Astellas Pharma Global Development, Inc. · NCT07425574A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Phase N/A · 1 location(s) · Nanoscope Therapeutics Inc. · NCT06805474Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degener
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT06375239Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4
Phase N/A · 1 location(s) · National Eye Institute (NEI) · NCT04591483Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease
Phase 1/Phase 2 · 1 location(s) · VeonGen Therapeutics GmbH · NCT07002398A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
Phase 1/Phase 2 · 8 location(s) · AAVantgarde Bio Srl · NCT07161544Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT07502664Rod and Cone Mediated Function in Retinal Disease
Phase N/A · 1 location(s) · National Eye Institute (NEI) · NCT02617966Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients
Phase 1/Phase 2 · 3 location(s) · Ray Therapeutics, Inc. · NCT07439887Stem Cell Ophthalmology Treatment Study II
NA · 4 location(s) · MD Stem Cells · NCT03011541
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.